 Mina Nikanjam
|
| Title(s) | Assistant Clinical Professor, Medicine |
|---|
| School | Health Sciences |
|---|
| vCard | Download vCard |
|---|
|
|
 ORNG Applications Bibliographic
-
Lin S, Nikanjam M, Capparelli EV, Allegrini A, Pavone D, Yim DS, Hammami MM, Bertino JS, Nafziger AN, Park YS, Yin OQ, Ma JD. Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults. Ther Drug Monit. 2018 12; 40(6):754-758. PMID: 30045358.
-
Nikanjam M, Wing J, Capparelli E, Kurzrock R. Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. Cureus. 2018 Nov 26; 10(11):e3634. PMID: 30705793.
-
Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2018 Nov 01; 29(11):2192-2199. PMID: 30219896.
-
Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. J Clin Pharmacol. 2018 Dec; 58(12):1604-1617. PMID: 30252146.
-
Nikanjam M, Sun A, Albers M, Mangalindin K, Song E, Vempaty H, Sam D, Capparelli EV. Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience. J Pediatr Hematol Oncol. 2018 Jul; 40(5):e273-e277. PMID: 29771861.
-
Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS, Nafziger AN, Ma JD. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. J Clin Pharmacol. 2018 Sep; 58(9):1205-1213. PMID: 29663428.
-
Nikanjam M, Capparelli EV, Lancet JE, Louie A, Schiller G. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018 01; 81(1):171-178. PMID: 29167924.
-
Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun. 2017 08 14; 8(1):241. PMID: 28808226.
-
Nikanjam M, Patel H, Kurzrock R. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology. 2017; 6(8):e1338997. PMID: 28920006.
-
Nikanjam M, Liu S, Yang J, Kurzrock R. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist. 2017 05; 22(5):576-584. PMID: 28424323.
-
Nikanjam M, Liu S, Kurzrock R. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer. 2016 Nov 01; 139(9):2135-41. PMID: 27389805.
-
Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016 Mar 08; 7(10):11310-20. PMID: 26824502; PMCID: PMC4905475.
-
Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol. 2015 Mar; 75(3):495-503. PMID: 25557868.
-
Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother. 2012 Oct; 56(10):5374-80. PMID: 22869579; PMCID: PMC3457371.
-
Nikanjam M, Chadwick EG, Robbins B, Alvero C, Palumbo P, Yogev R, Pinto J, Hazra R, Hughes ML, Heckman BE, Capparelli EV. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing. Clin Pharmacol Ther. 2012 Feb; 91(2):243-9. PMID: 22190064; PMCID: PMC3356582.
-
Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV. Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol. 2012 Dec; 52(12):1824-32. PMID: 22180560; PMCID: PMC3369109.
-
Sleasman JW, Robbins BL, Cross SJ, Lindsey JC, Kraimer JM, Heckman BE, Sprenger HL, Tustin NB, Rose CH, Poston PA, Neal EF, Pakes GE, Nikanjam M, Capparelli EV. Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. Clin Pharmacol Ther. 2009 Apr; 85(4):394-401. PMID: 19118380; PMCID: PMC2767189.
-
Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 2007 Dec 20; 124(3):163-71. PMID: 17964677.
-
Nikanjam M, Kursa K, Lehman S, Lattanza L, Diao E, Rempel D. Finger flexor motor control patterns during active flexion: an in vivo tendon force study. Hum Mov Sci. 2007 Feb; 26(1):1-10. PMID: 17173995.
-
Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm. 2007 Jan 02; 328(1):86-94. PMID: 16959446.
|
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|